Application of the CARE guideline as reporting standard in the Translational Cancer Research

The Translational Cancer Research welcomes case reports which are supposed to report new observations of diseases, clinical findings or novel/unique treatment outcomes relevant to practitioners in the fields of medicine.

For completeness and transparency for published case reports, the Translational Cancer Research will apply the CARE guidelines (1) as reporting standards for case reports starting from October 14, 2019. For any submission of case report after the date:

1. The author should prepare the manuscript according to the CARE guideline and indicate at the end of the Introduction section that the case report is presented in accordance with the CARE Guideline. The wording of the indication could be “We present the following case in accordance with the CARE guideline”. For the example, please refer to the article “Werthmann PG, Saltzwedel G, Kienle GS. Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts—a case report” (2).

2. The CARE checklist (3) should be provided as an additional file. Submissions received without the Checklist will be returned to the authors as incomplete. The checklist will not be employed as a norm for judging the suitability of manuscripts for publication, but it is intended as an aid to authors to entirely and transparently let reviewers and readers know what authors did and found.

For more detailed information, please refer to the journal’s author instruction.